Skip to main content

Vimpat News

Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

ATLANTA, Nov. 17, 2020 /PRNewswire/ – UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Seizures, Epilepsy

Vimpat patient information at Drugs.com